Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Aug 19, 2021 8:00pm
197 Views
Post# 33737755

RE:RE:Don't lose sight of what's important ...

RE:RE:Don't lose sight of what's important ...As with any company - some are there only to collect a paycheck.
I don't think that's the case with Dan, John or Joe.
Sure we can say it when we're angry that things aren't going our way - but it doesn't really paint a true picture.
There's a real product here and development work isn't easy.
That's just a fact ... and ... it makes investing in it difficult.
Thick skin - that's what it takes !!!!



StockingUp21 wrote:

so do AME First before waist time on new phase 11. But sure they will drag out to collect oaycheque for another 2 years before we lose everything .

 

MrMugsy wrote: Can the dose go lower?
The market has hated this unknown so we need to figure it out.
MIght need AME #2 as we look at 75,50,25 mg
Might need AME #3 as we look at 25,15,10 mg if we still don't know the lowest possible dose.
Either way, there are higher dose and lower dose options for this drug.

Nice to see that a replacement for 352 is also in the cards for this one - with potential for fast-track.

5 weeks - get an idea of where we are going.
Is the liver constantly bathing in Naproxen? 
Just might be the case.

Once we have it figured out and on our way - hoping we are further derisked and much more valuable to a partner.  

 

 



<< Previous
Bullboard Posts
Next >>